Literature DB >> 30557221

Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.

Florentia Dimitriou1, Joanna Mangana, Sara Micaletto, Ralph P Braun, Reinhard Dummer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30557221     DOI: 10.1097/CMR.0000000000000544

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


× No keyword cloud information.
  3 in total

Review 1.  Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.

Authors:  Adam Amlani; Claire Barber; Aurore Fifi-Mah; Jose Monzon
Journal:  Oncologist       Date:  2020-06-02

2.  Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.

Authors:  Harish Seethapathy; Meghan D Lee; Ian A Strohbehn; Orhan Efe; Nifasha Rusibamayila; Donald F Chute; Robert B Colvin; Ivy A Rosales; Riley M Fadden; Kerry L Reynolds; Ryan J Sullivan; Howard L Kaufman; Kenar D Jhaveri; Meghan E Sise
Journal:  Nephrol Dial Transplant       Date:  2022-02-25       Impact factor: 5.992

Review 3.  Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy.

Authors:  Zhujiang Dai; Jihong Fu; Xiang Peng; Dong Tang; Jinglue Song
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.